MOTS-c: The mitochondrial performance switch
At a glance
What the mouse data shows
MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded by a short open reading frame in the mitochondrial 12S rRNA region, and the core mouse literature frames it as an exercise-responsive regulator of skeletal-muscle and adipose metabolism rather than as a simple stimulant or appetite suppressant.
The strongest mouse data are in metabolically stressed animals: high-fat diet, aging, ovariectomy, immobilization, and cold exposure models, where MOTS-c repeatedly improves glucose handling, energy expenditure, muscle metabolic signaling, thermogenic fat activation, or muscle preservation.
For performance, the most compelling mouse papers show that MOTS-c improves treadmill capacity across young, high-fat-fed, middle-aged, and old mice, with old 22-month mice running about 2-fold longer and 2.16-fold farther after short-term treatment in one study. A separate acute-performance study found that a single 15 mg/kg intraperitoneal dose given 10 minutes before an exercise test increased running time by 12% and distance by 15% in untrained young female mice.
Performance signal
Old mice ran 2× longer; young mice improved 12–15% with a single pre-test dose in crossover trial.
Fat loss model
MOTS-c prevented high-fat diet obesity and ovariectomy fat gain without reducing food intake, mainly through thermogenesis and AMPK.
Muscle preservation
MOTS-c reduced muscle atrophy by ~10% during immobilization and lowered myostatin ~40% in obese mice.
The big idea
MOTS-c looks like a mitochondrial stress-adaptation signal: when metabolism is under strain, it pushes tissues toward better fuel handling, glucose uptake, thermogenesis, and muscle resilience. That is why the mouse data are most impressive in “challenged” states such as high-fat diet, aging, ovariectomy, immobilization, and cold exposure rather than in already-healthy animals.
The simplest model is: exercise or mitochondrial stress increases MOTS-c, MOTS-c engages AMPK/PGC-1α and CK2-linked pathways, muscle becomes more metabolically flexible, adipose tissue becomes more thermogenic, and whole-body physiology shifts away from insulin resistance and fat storage under stress.
Most interesting mouse studies
| Study | Why it is cool | Performance/composition signal |
|---|---|---|
| Reynolds et al., 2021 | The best “performance and aging” paper: MOTS-c improved exercise capacity in young, middle-aged, old, and late-life-treated mice. | Old 22-month mice ran about 2-fold longer and 2.16-fold farther; late-life intermittent treatment improved grip strength, gait, and fat mass at very old age. |
| Lee et al., 2015 | The foundational fat-loss/metabolic-homeostasis paper: MOTS-c prevented high-fat diet obesity without reducing food intake. | MOTS-c prevented high-fat diet-induced body-weight gain, hyperinsulinemia, and hepatic lipid accumulation despite identical caloric intake, while increasing heat production and respiratory exchange ratio. |
| Hyatt, 2022 | The cleanest acute “performance pop” result: one MOTS-c dose improved a treadmill test in untrained mice. | MOTS-c increased total running time by 12% and distance by 15%; 5 of 6 MOTS-c-treated mice exceeded 40 minutes versus none after saline. |
| Yang et al., 2021 | The best “MOTS-c plus exercise” synergy study: exercise and MOTS-c together improved obesity-linked metabolic signals more than either alone. | Exercise, MOTS-c, and the combination reduced body weight and insulin, with the combination described as synergistic and independent of food intake. |
| Lu et al., 2019 | The strongest female/metabolic-hormone model: MOTS-c countered ovariectomy-induced weight and fat gain. | MOTS-c prevented ovariectomy-induced body-weight gain and insulin resistance, reduced fat mass, activated brown fat, and suppressed adipose inflammation. |
| Xue et al., 2019 | A thermogenesis paper that helps explain why MOTS-c could affect fat-loss physiology without directly suppressing appetite. | MOTS-c maintained higher acute-cold body temperature, reduced triglyceride rise, upregulated BAT PGC1α/UCP1/Dio2, and promoted white-fat browning. |
| Sato/Kumagai et al., 2024 | A “body recomposition” study: MOTS-c preserved muscle and reduced muscle lipid infiltration during immobilization. | Immobilization reduced muscle mass by ~15%, while MOTS-c attenuated the loss to ~5%; MOTS-c also lowered muscle fatty-acid levels. |
| Kumagai et al., 2024 | The most important mechanism paper: it identifies CK2 as a direct functional target of MOTS-c. | MOTS-c enhanced gastrocnemius glucose uptake, prevented immobilization atrophy, directly bound CK2α, and required CK2 activity for muscle effects. |
Performance data
Chronic MOTS-c: endurance and healthspan — The Reynolds 2021 paper is the highest-impact performance study because it tested MOTS-c across age and metabolic contexts. Young high-fat-fed CD-1 mice needed 10 days of 15 mg/kg/day MOTS-c to show superior running performance, while old 22-month C57BL/6N mice ran about twice as long and more than twice as far as untreated old mice.
Acute MOTS-c: single-dose treadmill signal — The Hyatt 2022 study used a crossover design where each untrained female mouse served as its own control. A single 15 mg/kg IP dose given 10 minutes before the test increased total running time by 12% and distance by 15%, with all six mice doing better on MOTS-c than saline.
Exercise-induced endogenous MOTS-c — Exercise itself appears to induce MOTS-c in muscle and circulation. In rodents, 4 to 8 weeks of voluntary running increased MOTS-c protein expression roughly 1.5- to 5-fold in multiple skeletal muscles. In humans, acute high-intensity cycling increased skeletal-muscle MOTS-c about 11.9-fold and plasma MOTS-c about 1.5- to 1.6-fold.
Fat loss and body composition
High-fat diet obesity prevention — The original Cell Metabolism study provides the strongest fat-loss-adjacent result: MOTS-c prevented high-fat diet-induced obesity in mice without changing food intake. The high-fat diet protocol used 60% calories from fat, and MOTS-c at 0.5 mg/kg/day IP prevented body-weight gain, hyperinsulinemia, and hepatic lipid accumulation with identical caloric intake.
Exercise plus MOTS-c in obese mice — The Yang 2021 study models a realistic “peptide plus exercise” concept. After 11 weeks of high-fat diet, mice received treadmill exercise, 0.5 mg/kg/day MOTS-c, or the combination for 8 weeks. The combination reduced body weight and insulin concentrations and synergistically increased skeletal-muscle MOTS-c, PGC-1α, GLUT4, p-AMPK, and p-ACC.
Ovariectomy-induced fat gain — The Lu 2019 ovariectomy paper extends MOTS-c beyond male high-fat diet models into a female low-estrogen metabolic-stress model. MOTS-c prevented ovariectomy-induced body-weight gain and insulin resistance, reduced fat mass, activated brown fat, and suppressed inflammatory invasion in white adipose tissue.
Muscle preservation and recomposition
MOTS-c has a surprisingly strong muscle-preservation signal in obesity and immobilization models. In high-fat diet mice, MOTS-c prevented decreases in skeletal-muscle index and reduced myostatin expression, while a separate long-term high-fat diet experiment showed plasma myostatin about 40% lower after MOTS-c treatment.
The immobilization study is even cleaner for muscle preservation because casting reduced muscle mass by about 15%, while MOTS-c limited the reduction to about 5% after 8 days. MOTS-c also lowered muscle fatty-acid levels, increased ANGPTL4, suppressed inflammatory cytokines including IL-1β, IL-6, CXCL1, and MCP-1, and normalized AKT/FOXO signaling in immobilized mice.
Mechanism map
| Mechanism | What MOTS-c appears to do | Why it matters |
|---|---|---|
| AMPK/AICAR axis | MOTS-c inhibits folate-methionine and de novo purine synthesis at the 5Me-THF level, leading to AICAR accumulation and AMPK activation. | AMPK activation is a central energy-stress signal that supports glucose uptake, fatty-acid handling, and metabolic remodeling under exercise or diet stress. |
| PGC-1α/GLUT4 | Exercise, MOTS-c, and their combination increased skeletal-muscle PGC-1α, GLUT4, p-AMPK, and p-ACC in high-fat diet mice. | PGC-1α and GLUT4 are central to mitochondrial adaptation and glucose uptake, which connects MOTS-c to endurance and insulin sensitivity. |
| CK2 binding | MOTS-c directly bound CK2α, activated CK2 in skeletal muscle, and required CK2 activity for its muscle glucose-uptake effect. | This gives MOTS-c a concrete proximal target and links it to muscle glucose uptake and atrophy prevention. |
| Myostatin/AKT/FOXO | MOTS-c reduced plasma and muscle myostatin in diet-induced obese mice and modulated PTEN/mTORC2/AKT/FOXO1 signaling. | Lower myostatin and atrophy signaling may support lean-mass preservation during obesity, disuse, or aging stress. |
| Adipose thermogenesis | MOTS-c increased BAT UCP1/PGC1α/Dio2 signaling, promoted inguinal WAT browning features, and increased adipose oxygen-consumption signals. | Thermogenic fat activation can increase energy expenditure in rodents, but the same magnitude should not be assumed in humans. |
| Lipid-metabolite cleanup | In diet-induced obese mice, MOTS-c reduced plasma sphingolipid, monoacylglycerol, and dicarboxylate pathways upregulated in obesity and type 2 diabetes models. | Lower sphingolipid and dicarboxylate signals are consistent with improved insulin sensitivity and more efficient fatty-acid oxidation. |
What the data does not prove
The current evidence does not prove that exogenous MOTS-c causes clinically meaningful fat loss in humans, because the strongest fat-loss data are rodent studies and the human literature is still mostly biomarker or exercise-association evidence. The current evidence also does not prove that MOTS-c improves human athletic performance, because the mouse treadmill studies are preclinical and human exercise studies mainly show that endogenous MOTS-c rises with exercise rather than that injected MOTS-c improves performance.
The mouse fat-loss signal should be interpreted as metabolic-state dependent, because MOTS-c had strong effects in high-fat diet and ovariectomy models but little effect on body weight in normal-diet mice in the foundational work. The thermogenesis data are also rodent-specific in an important way, because mouse brown/beige fat biology and housing temperature can substantially influence energy-expenditure phenotypes.
The dosing in many mouse studies used intraperitoneal injections such as 0.5, 5, or 15 mg/kg/day, and those regimens cannot be directly converted into safe or effective human use without clinical pharmacology and safety data. A Phase 2a randomized placebo-controlled clinical trial is evaluating 12 weeks of subcutaneous MOTS-c in adults with prediabetes and overweight/obesity, with insulin sensitivity and adverse events among the listed outcomes, but the extracted record did not show posted results.
Bottom line
The mouse data support MOTS-c as a mitochondrial exercise-mimetic and metabolic-resilience peptide with three standout effects: better exercise capacity in aging or metabolically challenged mice, reduced fat accumulation and insulin resistance under high-fat diet or ovariectomy stress, and preserved muscle mass/signaling under obesity or immobilization stress.
The most exciting practical interpretation is not that MOTS-c is merely a “fat-loss peptide,” but that it appears to make stressed muscle and fat behave more like trained, metabolically flexible tissue.
